Pre-IPO Secondary Vetting Report
How a 500-credit Pre-IPO Secondary Vetting Report is produced. The frameworks we adopt, the cap-table-opacity boundary we will not pretend to overcome, and the corrections process if we get something wrong.
Overview
A Pre-IPO Secondary Vetting Report is a paginated, twelve-section due-diligence document on a private pre-IPO company being evaluated for a secondary stake purchase. It is generated on demand from SEC Form D filings, public funding-round announcements, public LinkedIn signals, secondary-marketplace public listings (Forge / EquityZen / Hiive), and Serper press search. It takes three to five minutes to produce, costs 50 credits (about $20 USD), and is delivered as a shareable HTML report with a printable PDF view.
It is intended for an accredited investor evaluating a Forge / EquityZen / Hiive listing, a family office doing direct secondary purchases, or a syndicate pooling capital for a secondary deal.
The Five Frameworks We Adopt
ICD 203 — Analytic Standards (Office of the Director of National Intelligence)
The U.S. Intelligence Community’s Directive 203 defines nine tradecraft standards. We treat these as binding for every Pre-IPO Secondary Vetting Report. The discipline of expressing uncertainty explicitly is non-negotiable when reconstructing cap tables from public signals.
UK PHIA Probability Yardstick (UK Defence Intelligence)
Every probabilistic claim — founder credibility, IPO trajectory probability, liquidation-preference overhang estimation, secondary-pricing implied valuation — is expressed using the seven-band PHIA yardstick paired with an analytical-confidence rating.
Founder Due Diligence Methodology (MentionFox)
Section 3 (Founder & Team Full Due Diligence) applies the Founder Due Diligence methodology that anchors the Founder Vetting Report (vertical 1): named founder track record across prior shipped projects, prior funding history, prior employment at recognised brands, public-credibility signals, prior SEC enforcement / public litigation. For pre-IPO companies, founder credibility is a primary value-driver and warrants person-level Due Diligence.
Counterparty Due Diligence Framework (MentionFox)
Section 4 (Company Entity Audit) applies the Counterparty Due Diligence framework that anchors the Counterparty Vetting Report (vertical 10): legal name, jurisdiction of incorporation (Delaware C-corp standard for VC-backed companies), registered address, prior name changes, regulatory enforcement, related-party transactions disclosed in funding-round documents.
SEC Accredited-Investor Framework
The SEC’s accredited-investor definition under Rule 501 of Regulation D governs eligibility for unregistered private-securities purchases — including pre-IPO secondary stakes. The Pre-IPO Secondary Vetting Report is research synthesis for accredited investors who are already eligible to purchase such stakes. The methodology page’s use-disclosure banner reflects this constraint explicitly: this report is not for non-accredited investors and the underlying secondary marketplaces (Forge / EquityZen / Hiive) gate access at the accredited-investor threshold per their compliance programmes.
The Twelve Sections of a Pre-IPO Secondary Vetting Report
| # | Section | Purpose |
|---|---|---|
| 1 | Executive Summary | Built last. Recommended action, four-axis risk posture, why-consider bullets, what-to-verify bullets. |
| 2 | Pre-IPO Risk Assessment | Score out of 100 with four sub-scores: founder track, cap table integrity, IPO trajectory probability, secondary liquidity. |
| 3 | Founder & Team Full Due Diligence | Founder Due Diligence applied per founder; leadership team coverage where named. |
| 4 | Company Entity Audit | Counterparty Due Diligence applied to the company entity. |
| 5 | Cap Table Full Reconstruction | SEC Form D + funding-round announcements + standard dilution math; PHIA-banded estimates with explicit gap disclosure. |
| 6 | Recent Round Terms Analysis | Last round size + pre/post-money + lead + structural terms (liq-pref, anti-dilution, board, protective). |
| 7 | Revenue & Growth Trajectory | Disclosed revenue, named customer wins, hiring velocity (LinkedIn signal). |
| 8 | IPO Pipeline Signals | S-1 rumors, banker selection, lockup-prep, comparable-peer IPO timing. |
| 9 | Secondary Market Pricing | Forge / EquityZen / Hiive bid-ask spreads + volume + implied valuation. |
| 10 | Liquidation Preference Overhang | Estimated participation by series; common-equity haircut breakeven analysis. PRIMARY risk axis for secondary buyers. |
| 11 | Red Flags — Severity-Ranked | HIGH / MEDIUM / LOW aggregate. |
| 12 | References & Source Citations | Aggregated audit trail of every URL cited above, deduplicated, grouped by source class per ICD 206. |
Cap Table Reconstruction — How We Apply It
Private-company cap tables are confidential by design. The Pre-IPO Secondary Vetting Report does not pretend to know what the actual cap table contains. Instead, Section 5 reconstructs an APPROXIMATE cap table from publicly-disclosed signals + standard-dilution-math inference:
- SEC Form D filings. Every U.S. private-company round filed under Regulation D requires Form D submission to SEC EDGAR within 15 days of first sale. Form D discloses round size, total-amount-sold-to-date, and named selling commission recipients. We extract this directly. Public.
- Funding-round announcements. Press releases (TechCrunch, The Information, Bloomberg, Reuters) typically disclose round size, named lead investor, named participating investors, sometimes pre/post-money valuation, sometimes structural terms.
- Standard dilution math. Given disclosed round size + post-money valuation, we infer dilution per round (round size / post-money). Aggregating dilution across all disclosed rounds yields cumulative external-investor ownership; the residual is split between founders + employee pool per standard splits (typically 60-70% founders pre-Series-A, declining to 10-20% by late stage; employee pool typically 10-20% top-up at each round).
- Pitchbook / Crunchbase free-tier data where present. Free-tier data is incomplete but supplements the above for valuation history.
- Express in PHIA bands. Every reconstruction estimate is expressed as a PHIA-banded probability with confidence tier: "Realistic possibility (40-50%) founder allocation between 10-18% post-Series-E (Confidence: Low — inference from disclosed round sizes + standard dilution math; no internal cap-table access)."
Critical disclaimer: cap-table reconstruction is approximate. Actual founder allocations, employee pools, and investor stakes may differ from public-data inference by ±20% or more. The reconstruction is a starting point for buyer-side Due Diligence, not a substitute for buyer access to internal cap-table documents during a closing.
Data Sources — Free Public Only
- SEC EDGAR Form D filings — every U.S. Reg D private-company round. Free + immediate.
- Public funding-round announcements — TechCrunch, The Information, Bloomberg, Reuters, founder Twitter, company press releases.
- PitchBook / Crunchbase free tiers — supplementary valuation history where present.
- Public LinkedIn signals — employee-count growth as proxy for go-to-market / R&D investment.
- Secondary-marketplace public listings — Forge, EquityZen, Hiive, AngelList Secondary, Carta CartaX. We use only the public-facing listing data; we do not access account-gated content.
- SEC enforcement actions database — for any prior enforcement against named officers or the company entity.
- Serper — for general press / news search (IPO pipeline rumors, banker-selection signals, customer-win press).
What we do NOT use: PitchBook full subscription data, Crunchbase Pro full data, Bloomberg Terminal cap-table tools, internal data rooms, or any account-gated secondary marketplace content.
Honest Limits — what we do not do
What we DO do
- Synthesis-tier output: 12-section narrative Due Diligence report sourced from free public APIs with cited URLs.
- Public methodology: this page. Frameworks auditable by accredited investors, family-office Due Diligence teams, and the secondary-marketplace platforms themselves.
- Asymmetric pricing: 50 credits (about $20) for a full vetting report. Comparable depth via PitchBook + Crunchbase Pro subscriptions costs thousands per seat per year.
- Adopted intelligence-community + MentionFox-original frameworks (ICD 203, ICD 206, UK PHIA, Founder Due Diligence, Counterparty Due Diligence, SEC accredited-investor framework, ALCOA) in writing, openly.
What we DO NOT do
- We do not access private cap-table documents. Reconstruction is approximate from public signals.
- We do not predict IPO timing as a binary outcome. PHIA bands carry probability where evidence supports inference.
- We do not access subscription analytics platforms (PitchBook full, Crunchbase Pro full, Bloomberg Terminal).
- We do not access account-gated secondary-marketplace content (Forge / EquityZen / Hiive member-only listings).
- We do not contact the company, founders, or named investors to gather information.
- We do not give investment advice. The report is research synthesis for accredited investors; purchase decisions remain with the buyer.
- We do not invent claims to fill thin sections.
Corrections Policy
Three commitments modeled on the BBC editorial corrections process:
- Identification window. Errors flagged within thirty days of report generation are corrected on the canonical view URL within five business days.
- Re-publication, not silent edit. Corrections preserve a redline diff between the original and corrected text, time-stamped, with a one-line explanation.
- Subject right of reply. The company named in any Vetting Report may submit a one-paragraph factual rebuttal to corrections@mentionfox.com. Verifiable rebuttals attach to the report alongside the original section.
Data integrity floor — ALCOA. Every Pre-IPO Secondary Vetting Report carries an ALCOA Methodology footer.
References
- SEC EDGAR Form D filings — U.S. Securities and Exchange Commission.
- SEC Regulation D — private-securities exemption framework.
- SEC accredited-investor definition (Rule 501 amendment, 2020).
- Forge — public listing data.
- EquityZen — public listing data.
- Hiive — public listing data.
- ICD 203 — Analytic Standards — Office of the Director of National Intelligence (2015).
- ICD 206 — Sourcing Requirements for Disseminated Analytic Products.
- UK PHIA Probability Yardstick.
- FDA Data Integrity and Compliance With Drug CGMP — ALCOA principles.
Methodology v1.0 · Published 2026-05-04 · Verifierce / MentionFox · Vertical M5 of the Due Diligence PlatformSPAC Sponsor methodology →